© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
FDA weighs whether to resume coronavirus vaccine trial halted due to an adverse event.
A U.K. woman developed spinal inflammation after receiving an adenovirus vector vaccine.
Public health departments are now being told to prepare to distribute COVID-19 vaccines as early as November 1.
“Will we have a COVID vaccine next year tailored to the obese? No way."
National Academies recommends a four-phased approach to maximize societal benefit by reducing morbidity and mortality.
The FDA must approve any coronavirus vaccine before it’s widely distributed, but political pressure could cloud the decision.
The trial will enroll healthy volunteers to test the vaccine’s safety and ability to trigger an immune response.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
